Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro

Citation metadata

Publisher: Contexto
Document Type: Report
Length: 2,728 words
Lexile Measure: 1750L

Document controls

Main content

Abstract :

Recent studies have shown that some drugs that are not routinely used to treat fungal infections have antifungal activity, such as protease inhibitor antiretroviral drugs. This study investigated the in vitro susceptibility of Histoplasma capsulatum var. capsulatum to saquinavir and ritonavir, and its combination with the antifungal itraconazole. The susceptibility assay was performed according to Clinical and Laboratory Standards Institute guidelines. All strains were inhibited by the protease inhibitor antiretroviral drugs. Saquinavir showed minimum inhibitory concentrations ranging from 0.125 to 1 [micro]g [mL.sup.-1] for both phases, and ritonavir presented minimum inhibitory concentrations ranging from 0.0312 to 4[micro]g [mL.sup.-1] and from 0.0625 to 1 [micro]g [mL.sup.-1] for filamentous and yeast phase, respectively. Concerning the antifungal itraconazole, the minimum inhibitory concentration values ranged from 0.0019 to 0.125 [micro]g [mL.sup.-1] and from 0.0039 to 0.0312 [micro]g [mL.sup.-1] for the filamentous and yeast phase, respectively. The combination of saquinavir or ritonavir with itraconazole was synergistic against H. capsulatum, with a significant reduction in the minimum inhibitory concentrations of both drugs against the strains (p Keywords: Histoplasma capsulatum Saquinavir Ritonavir Itraconazole

Source Citation

Source Citation   

Gale Document Number: GALE|A454782832